Menu
Back to Journals » Patient Preference and Adherence » Volume 15
Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]
Authors Senbel E, Tropé S , Herman-Demars H, Zinovieva E, Courbeyrette A, Clerson P , Fardini Y, Flipo RM
Received 20 July 2021
Accepted for publication 20 July 2021
Published 27 July 2021 Volume 2021:15 Pages 1679—1680
Senbel E, Tropé S, Herman-Demars H, et al. Patient Prefer Adherence. 2021;15:751–760.
Page 751, Abstract, Results section, the text “Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even in patients with unchanged MTX dose” should read “Switch to SC route increased the proportion of patients with remission or LDA from 22.2% to 52.3% and increased quality of life even in patients with unchanged MTX dose”.
The authors apologize for this error.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.